Production issues now resolved, manufacturer tells TGA
Manufacturing issues that led to a shortage of the impetigo treatment Bactroban have been resolved, the TGA says.
GSK, manufacturer of the treatment has advised that “the shortage of Bactroban (mupirocin) 20 mg/g ointment tube has been resolved”.
“Manufacturing issue that resulted in the unavailability of the medicine has been addressed and that the registered product is now available through the normal supply chains,” the company informed the TGA.
“The unapproved product…. that was available as an alternative due to the shortage [Mupirocin 20 mg/g ointment] is no longer available under section 19A of the Therapeutic Goods Act 1989,“ the TGA says.
The shortage had been first noted in May 2016.
Click here for more information
For more information on all ongoing, or predicted, shortages, visit the TGA’s Medicines Shortages Information site
